Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Alacrita LLP. (3/2/13). "Press Release: Alacrita Proud to Have Advised Menarini on Its Strategic Alliance with Oxford Biotherapeutics".

Organisations Organisation Alacrita LLC
  Group Alacrita (Group)
  Organisation 2 Menarini (Group)
Products Product consulting, business
  Product 2 antibody cancer drug
Index term Index term Menarini–Oxford BioTherapeutics: antibody cancer drug, 201210– strategic alliance to develop 5 of OBT’s AB + ADC programs
Persons Person Slade, Andrew (Menarini 201303 President of Menarini Biologics)
  Person 2 Walker, Anthony (Alacrita 2009– Founding Partner before Onyvax CEO + co-founder before consultant)
     


Alacrita is proud to have advised Menarini on its major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer. Signed in October 2012, the deal brings together OBT's discovery expertise with Menarini's clinical and biologics manufacturing and development capability, to build value for both companies as they work to bring the next generation of antibody-based cancer drugs to market.

The transaction has been nominated by Deloitte as a candidate for the Breakthrough Alliance Award.

Andrew Slade, President of Menarini Biologics, said "This is a transformational deal for Menarini, paving the way for the development and manufacture of up to five new cancer therapeutics and a total investment of €800m. Alacrita's team of expert consultants provided valuable support throughout the assessment of the opportunity. They helped frame the OBT deal in the context of other transactions we were considering and helped us communicate the strategic value of the alliance to our internal stakeholders. Their technical, regulatory, and commercial insight was impressive and enabled us to structure the alliance to maximize success for both parties".

Anthony Walker, Partner at Alacrita, said "We congratulate Menarini and OBT on closing the transaction and wish them every success in their mission to develop better cancer medicines. We are also delighted that the transaction has been recognized by Deloitte as a breakthrough alliance. Alacrita is committed to helping life science companies navigate the complexities of today's global market, ensuring new medical products reach the market and meet the needs of patients".


About Menarini Group

Menarini is an international pharmaceutical company which, with a 2011 consolidated worldwide turnover of more than 3 billion Euro, ranks 17th in Europe and 34th world-wide.

Menarini's territorial presence covers more than 100 countries in Europe, Africa, Asia, Australia and Latin America, with 15.000 headcount. Menarini was founded 125 years ago and currently markets products for the most important therapeutic fields: respiratory, cardiovascular, gastroenterology, oncology, metabolism, antibiotics, diabetes, anti-inflammatories and analgesics. The Menarini Group has always pursued two strategic objectives: Research and Internationalisation, both of which have allowed it to achieve outstanding results in today's global market and invest in the research of innovative drugs, making them available to patients all around the world.

   
Record changed: 2018-10-31

Advertisement

Picture [iito] – Putting Information into Context 600x60px

More documents for Alacrita (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top